论文部分内容阅读
目的观察依达拉奉对急性脑梗死患者血清NF-κB和sICAM-1表达的影响及其疗效。方法60例急性脑梗死患者随机分为治疗组和对照组,对照组按急性脑梗死常规治疗方法治疗,治疗组在常规治疗基础上加用依达拉奉。检测治疗前、治疗后3d、7d、14d血清中NF-κB和sICAM-1的浓度。评定入院时、治疗后3d、7d、14d、28d、60d的神经功能缺损和60d后疗效。结果与对照组相比,依达拉奉治疗组的神经功能恢复均较对照组明显(P<0.001),依达拉奉治疗组的疗效明显优于对照组(P<0.001),且依达拉奉治疗组血清中NF-κB和sICAM-1的浓度降低幅度均较对照组明显(P<0.001)。结论依达拉奉可以减轻急性脑梗死缺血性脑损伤,其神经保护机制可能与抑制NF-κB和sICAM-1的表达,阻断炎症级联反应有关。
Objective To observe the effect of edaravone on the expression of NF-κB and sICAM-1 in patients with acute cerebral infarction and its curative effect. Methods Sixty patients with acute cerebral infarction were randomly divided into treatment group and control group. The control group was treated by conventional treatment of acute cerebral infarction. The treatment group was given edaravone on the basis of routine treatment. The concentrations of NF-κB and sICAM-1 in serum before treatment, 3d, 7d, 14d after treatment were detected. Evaluate the neurological deficit and the efficacy after 60 days on admission, 3 days, 7 days, 14 days, 28 days and 60 days after treatment. Results Compared with the control group, the recovery of neurological function in edaravone group was significantly higher than that in control group (P <0.001), and that in edaravone group was significantly better than that in control group (P <0.001) The decrease of serum NF-κB and sICAM-1 in Laval treatment group was more significant than that in control group (P <0.001). Conclusion Edaravone can attenuate ischemic brain injury induced by acute cerebral infarction. The neuroprotective mechanism may be related to inhibiting the expression of NF-κB and sICAM-1 and blocking the inflammatory cascade.